Skip to main content
OpenTrials
Completed

NCT Number: NCT01608061

ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease

The primary objective of this feasibility study is to evaluate the safety of DBS-f in patients with mild Alzheimer's disease by assessing all device and/or therapy related adverse events. The secondary objective is to preliminarily estimate the treatment effect size on the outcomes of interest at 12 months post-randomization. The objectives do not involve formal tests of hypotheses.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Age range

45 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Toronto Western Hospital, Toronto, Ontario, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 45-85 years of age (inclusive)
  • Probable Alzheimer's disease according to the National Institute of Aging Alzheimer's disease Association criteria.
  • Must meet certain criteria on cognitive and behavioral rating scales
  • If female, subjects who are post-menopausal or surgically sterile or willing to use birth control methods for the duration of the study.
  • An available caregiver willing to participate.
  • Subject is living at home and likely to remain at home for the study duration.
  • The subject is currently taking a stable dose of cholinesterase inhibitor (AChEI) medication for at least 60 days

Exclusion criteria

  • Must meet certain criteria on cognitive and behavioral rating scales
  • Current major psychiatric disorder such as schizophrenia, bipolar disorder or major depressive disorder based on psychiatric consult at screening visit
  • History of head trauma in the 2 years prior to signing the consent to participate in the study
  • History of brain tumor, subdural hematoma, or other clinically significant (in the judgment of the investigator) space-occupying lesion on CT or MRI
  • Active psychiatric disorder
  • Mental retardation
  • Current alcohol or substance abuse as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
  • Contraindications for PET scanning (e.g., insulin dependent diabetes)
  • Contraindications for MRI scanning, including implanted metallic devices (e.g. non-MRI-safe cardiac pacemaker or neurostimulator; some artificial joints metal pins; surgical clips; or other implanted metal parts), or claustrophobia or discomfort in confined spaces.
  • Abnormal lab results that, in the opinion of the investigator and/or enrollment review committee, would preclude participation in the study.
  • Abnormal cardiovascular or neurovascular disorder that, in the opinion of the investigator and/or enrollment review committee, would preclude participation in the study.
  • Unstable doses of any medication prescribed for the treatment of memory loss or Alzheimer's disease.
  • Currently prescribed any non-AD medications that, in the opinion of the investigator and/or enrollment review committee, would preclude participation in the study.
  • Is unable or unwilling to comply with protocol follow-up requirements.
  • Has a life expectancy of < 1 year.
  • Is actively enrolled in another concurrent clinical trial.

Treatment and study plan

DBS-f On

Device

deep brain stimulation of the fornix

Other names: DBS-f system includes:, *Medtronic Activa PC Model 37601 Implantable Neurostimulator (INS), *Medtronic Model 3387 DBS Lead, *Medtronic Model 37085 DBS Extension Kit, *Medtronic Model 3708660 DBS Extension Kit

DBS-f off

Device

deep brain stimulation of the fornix turned off

Other names: DBS-f system includes:, *Medtronic Activa PC Model 37601 Implantable Neurostimulator (INS), *Medtronic Model 3387 DBS Lead, *Medtronic Model 37085 DBS Extension Kit, *Medtronic Model 3708660 DBS Extension Kit

Primary outcomes

  1. Acute Safety

    Time frame: 30 days post implant

    Acute safety will be assessed by estimating the rate of serious device (pulse generator or lead) or procedure related adverse events from the date of implant through the date of randomization, plus serious procedure related events through 30 days post-implant. All subjects undergoing an implant procedure will be included in these rate estimates. The rate and 95% confidence interval will be presented. Analysis is of a timepoint prior to randomization and thus all subjects are analyzed together.

  2. Long Term Safety. Not Based on Formal Hypotheses.

    Time frame: 12 month

    Long-term safety will be assessed by the rate of serious device or therapy related adverse events from the date of randomization through the date of the Month 12 visit. The rate and 95% confidence interval will be presented by randomization group. All subjects randomized will be included.

Secondary outcomes

  1. ADAS-Cog 13

    Time frame: Baseline and 12 months

    The mean change from baseline (pre-implant) to 12 months will be calculated in each treatment group. The differences between randomized groups in mean change will be calculated, along with corresponding 2-sided, 95% confidence intervals.

    Instrument is Alzheimer's Disease Assessment Scale - Cognitive subscale. Scores range from 0 to 85 with higher scores meaning worse outcome.

  2. CDR-SB

    Time frame: Baseline and 12 months

    The mean change from baseline (pre-implant) to 12 months will be calculated in each treatment group. The differences between randomized groups in mean change will be calculated, along with corresponding 2-sided, 95% confidence intervals.

    The scale used is the Clinical Dementia Rating Scale and the score used is the sum of boxes. The scores for this measure range from 0 to 18 with a higher score indicating a worse outcome.

Sponsors and collaborators

Lead sponsor

Functional Neuromodulation Ltd

Industry

Registry information

Official study title

A Twelve Month Double-blind Randomized Controlled Feasibility Study to Evaluate the Safety, Efficacy and Tolerability of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease

Acronym: ADvance

Important dates

Study start
2012
Primary completion
2015
Study completion
2018
First posted
May 30, 2012
Registry last updated
Aug 31, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.